TP53 and B-cell chronic lymphocytic leukemia: Next, other authors have attributed the differences in response to RTX treatment in CLL to IGHV mutational status [30] and to cytogenetic modifications and in particular to deletions at 11q/ATM or 17p/TP53 loci [43, 44].